Macular Edema and Degeneration Market Analysis Covering Drivers and Future Outlook
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Macular Edema and Macular Degeneration Market Expected To Change From 2026 To 2030?
The macular edema and macular degeneration market has experienced substantial expansion in recent years. It is projected to grow from $10.33 billion in 2025 to $11.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Historically, this growth has been driven by factors such as the increasing prevalence of diabetes and retinal disorders, an aging population facing a higher risk of vision impairment, the clinical success of anti-VEGF injections, rising awareness of macular diseases, and the expansion of ophthalmology clinics.
The macular edema and macular degeneration market size is projected to show significant expansion over the coming years. It is expected to reach $14.33 billion by 2030, progressing at a compound annual growth rate (CAGR) of 6.8%. This anticipated growth can be attributed to several factors including an expanding global diabetic population, intensified screening for retinal ailments, a rising demand for less invasive eye treatments, broader accessibility to advanced ophthalmic care, and increased healthcare investment in vision preservation. Noteworthy trends during the forecast period encompass a growing adoption of anti-VEGF based therapies, an increasing need for early diagnosis and timely intervention, a greater utilization of combined drug and laser treatments, an amplified emphasis on managing diabetic eye complications, and the expansion of outpatient and clinic-based eye care services.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
What Key Drivers Are Fueling The Growth Of The Macular Edema and Macular Degeneration Market?
The growing number of individuals with diabetes is projected to fuel the expansion of the macular edema and macular degeneration market moving forward. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood. This condition damages the blood vessels in the eye, which can result in macular edema and macular degeneration. For instance, in June 2024, according to The National Health Service (NHS England), a UK-based publicly funded healthcare system, in 2023, the number of people identified by the NHS in England as having pre-diabetes reached 3,615,330, representing an 18% increase from 3,065,825 in 2022. Additionally, among those under 40, cases rose by nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. Therefore, the increasing diabetes population is propelling the growth of the macular edema and macular degeneration market.
Which Segment Categories Are Included In The Macular Edema and Macular Degeneration Market Segment Analysis?
The macular edema and macular degeneration market covered in this report is segmented –
1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Subthreshold Laser Therapy, MicroPulse Laser Therapy
What Trends Are Influencing The Macular Edema and Macular Degeneration Market?
Major companies in the macular edema and macular degeneration market are prioritizing the development of innovative products, like continuous-delivery ocular implants, to lessen the burden of treatment, enhance patient adherence, and provide more consistent long-term therapeutic outcomes. These continuous-delivery ocular implants are small, refillable devices positioned in the eye that gradually dispense medication over several months, thereby assisting patients by reducing the requirement for frequent injections and offering consistent, long-term treatment for retinal diseases. For example, in February 2025, F. Hoffmann-La Roche Ltd, a Switzerland-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) approval for Susvimo. Susvimo is a refillable ocular implant designed to deliver the anti-VEGF drug ranibizumab for the management of diabetic macular edema (DME). Susvimo is conceptualized as a long-acting, surgically implanted reservoir that continuously releases a customized ranibizumab formulation, maintaining therapeutic drug levels for prolonged durations. In contrast to traditional anti-VEGF intravitreal injections that commonly demand monthly or bi-monthly dosing, Susvimo provides a refill-exchange interval of roughly six months, significantly lowering the patient’s treatment load. Its sustained-delivery approach boosts adherence, streamlines clinical workflow, and offers durable anatomical and visual benefits for patients experiencing chronic retinal disease.
Who Are The Active Companies Shaping The Macular Edema and Macular Degeneration Market?
Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.
Get The Full Macular Edema and Macular Degeneration Market Report:
Which Region Leads The Macular Edema and Macular Degeneration Market In Overall Market Size?
North America was the largest region in the macular edema and macular degeneration market in 2025. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Macular Edema and Macular Degeneration Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Macular Edema and Macular Degeneration Market 2026, By The Business Research Company
Macular Edema And Macular Degeneration Market Report 2026
Age Related Macular Degeneration Market Report
Retinal Disorder Treatment Market Report
https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
